Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
March 15, 2023 16:01 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced two presentations during the ACMG Annual Clinical Genetics Meeting,...
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 09, 2023 16:05 ET
|
Homology Medicines, Inc.
- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening - - Initial Clinical Data from Gene Therapy Trial for Hunter...
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
March 09, 2023 08:00 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical...
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
March 02, 2023 07:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive...
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting
February 22, 2023 16:01 ET
|
Homology Medicines, Inc.
Preclinical Studies Demonstrated a Targeted Immunosuppression Approach Led to Reduced Immune Response to AAVHSC Administration and Improved Gene Expression In Vivo Gene Therapy Candidate HMI-204 for...
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
January 04, 2023 16:01 ET
|
Homology Medicines, Inc.
Strong Cash Position with Runway into Fourth Quarter 2024 Non-Clinical Data on Immunosuppression Regimen Supportive of Clinical Programs Preclinical Data from HMI-103 Gene Editing Program Utilizing...
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
November 10, 2022 16:07 ET
|
Homology Medicines, Inc.
- On Track for Updates on pheEDIT and juMPStart Programs by Year-End - - Strong Financial Position with Cash Runway into Fourth Quarter 2024 - - Promoted Albert Seymour, Ph.D., to Chief Executive...
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
October 27, 2022 09:00 ET
|
Homology Medicines, Inc.
- Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design - BEDFORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq:...
Homology Medicines to Participate at Upcoming Conferences
October 06, 2022 08:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. ...
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
September 06, 2022 16:01 ET
|
Homology Medicines, Inc.
Arthur Tzianabos, Ph.D., Named Chairperson of the Board of Directors BEDFORD, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company,...